Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06706622 · ClinicalTrials.gov registry record · Phase 3

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

A Phase 3 study of Multiple System Atrophy, sponsored by H. Lundbeck A/S.

Active
Registry status
Phase 3
Development phase
357
Enrollment target
20
Study locations

NCT06706622 is a Phase 3 study of Multiple System Atrophy that is active but no longer recruiting, run by H. Lundbeck A/S. The registered enrollment target is 357 participants, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06706622, a Phase 3 study of Multiple System Atrophy, is active but no longer recruiting, sponsored by H. Lundbeck A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
357 participants
Enrollment target
20
Study locations

Study Summary

The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).

Conditions Studied

Multiple System Atrophy

Interventions

  • DRUG Placebo
  • DRUG Amlenetug

Study Locations (20)

Florida

  • Parkinson's Disease And Movement Disorder Center Of Boca Raton - Boca Raton
  • University of Florida Norman Fixel Institute for Neurological Diseases - Gainesville

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

New York

  • NYU Medical Center - Dysautonomia center - New York
  • Columbia University Medical Center - The Neurological Institute of New York - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • University Of Pittsburgh - Pittsburgh

Arizona

  • Mayo Clinic - Scottsdale

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

California

  • University of California, San Francisco Neurosciences Clinical Research Unit - San Francisco

Colorado

  • CenExel Rocky Mountain Clinical Research, LLC - Englewood

Trial Details

FieldValue
Enrollment Target 357 participants
Start Date 2024-12-03
Est. Completion 2029-10-25
Phase Phase 3

Sponsor

H. Lundbeck A/S

72 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06706622

The ClinicalTrials.gov registry entry for NCT06706622 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 257-participant average among 30 other Multiple System Atrophy trials with a reported enrollment target (39% higher). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple System Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06706622 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT06706622 about?

NCT06706622 is a clinical study titled "A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)". The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).

What is the current status of trial NCT06706622?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 357 participants. The study started on 2024-12-03. Estimated completion is 2029-10-25.

What conditions does trial NCT06706622 study?

This clinical trial studies the following conditions: Multiple System Atrophy.

What interventions are being tested in trial NCT06706622?

The interventions under investigation include: Placebo (DRUG), Amlenetug (DRUG).

Who is sponsoring clinical trial NCT06706622?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06706622 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple System Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple System Atrophy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.